ProShares Smart Materials ETFの空売り状況は、投資家がProShares Smart Materials ETFの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

ProShares Smart Materials ETF (ARCA:TINT), 空売り情報

Basic Materials

Technology

Industrials

Other

Healthcare

The Fund invests in financial instruments that ProShare Advisors believes, in combination, should track the performance of the Index. The Index is designed to measure the performance of companies that have business operations in the field of smart materials. The index provider uses a natural language processing algorithm to identify companies that fall into one or more of the following categories as (1) production of smart materials, also called intelligent or responsive materials, which can be defined as materials that have properties which can be changed by an external stimulus (such as temperature, electricity or stress), (2) production of materials with certain advanced, innovative, or disruptive qualities, and (3) development of technologies which promote advances and research related to smart materials.

Universal Display Corp

3m Co.

Corning Inc

Axalta Coating Systems Ltd

Dupont De Nemours Inc

Cabot

Applied Materials, Inc.

Sika Ag-Reg

Hexcel Corp

Lg Display Co Ltd

Applied Materials Inc

Merck & Co. Inc.

Chemours Co/The

Pfizer Inc

Arkema-sponsored Adr

Ppg Industries Inc

Akzo Nobel Nv - Spon ADR

Nidec Corp

Syensqo Sa

NVIDIA Corporation

Rpm International Inc

Proshares Smart Materials ETF

ProShares Smart Materials ETF

TINTIC STANDARD GLD MNS by Tintic Standard Gold Mines, Inc.

TINTRA PLC by Tintra PLC

Tintina Mines Ltd

Tintri Inc

Trading Ideas

HCHL

Happy City Holdings Shares Resume Trade

<a href="https://www.youtube.com/watch?v=iQAnZXa1Kpg">https://www.youtube.com/watch?v=iQAnZXa1Kpg</a>

Macro Economic Events

News

Politics

Economics

General

Fed Chair Powell Says It's A Question Of Being Prudent And Careful; Don't See Weakness In Labor Market; If Saw Labor Market Weakness We Would Change Things; As Long As Economy Strong We Can Take A Little Bit Of A Pause Here; If See Inflation Isn't Going To Increase, Or Labor Market Weaken, That Would Matter - Dont See It

TD Cowen analyst John Blackledge upgrades Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) from Hold to Buy and raises the price target from $16 to $21.

Upgrades

Price Target

Analyst Ratings

LYFT

TD Cowen Upgrades Lyft to Buy, Raises Price Target to $21

Fed Chair Powell Asked About Sept 2024 Half-Point Rate Cut, Says It Was The Rate Of Change With Unemployment Rate; Says If Not For Forecast Of Inflation, We Would Have Continued Cutting; Says We're Just Saying, Let's Wait And See More

Susquehanna analyst Bascome Majors downgrades CSX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) from Positive to Neutral and maintains the price target from $35 to $35.

Downgrades

Susquehanna Downgrades CSX to Neutral, Maintains Price Target to $35

First BanCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBP#NYSE">FBP</a>) has outperformed the market over the past 15 years by 15.13% on an annualized basis producing an average annual return of 27.64%. Currently, First BanCorp has a market capitalization of $3.28 billion. 
Buying $1000 In FBP: If an investor had bought $1000 of FBP stock 15 years ago, it would be worth $34,738.62 today based on a price of $20.30 for FBP at the time of writing.
<h3>First BanCorp's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750776720_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In First BanCorp 15 Years Ago Would Be Worth This Much Today

Fed Chair Powell Says Have To Wait And See, Which Is What We Are Doing; We Are At Higher Levels Of Rates, Significantly More Room To Cut Than There Was When Rates Were Near Zero

<a href="https://www.clevelandfed.org/collections/speeches/2025/sp-20250624-fourth-district-groundhog-in-londons-financial-district" title="https://www.clevelandfed.org/collections/speeches/2025/sp-20250624-fourth-district-groundhog-in-londons-financial-district">https://www.clevelandfed.org/collections/speeches/2025/sp-20250624-fourth-district-groundhog-in-londons-financial-district</a>

Federal Reserve

Fed's Hammack Says We Are Not Seeing A Move To Abandon Dollar By Investors But Moving To More Neutral Weight; No Need To Be Overly Dramatic About Shift Out Of Dollar

Fed Chair Powell Says Wouldn't Say Concerned Today About Govt Data, But Direction Is Concerning; Important For Fed, Congress, Businesses To Have Good Data;  Less Reliable, More Volatile Data Would Make It More Difficult For Private Sector, And Fed; We Expect Tariff Inflation To Show Up More, But Don't Know How Much To Be Passed To Consumers

Susquehanna analyst Bascome Majors upgrades Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) from Neutral to Positive and raises the price target from $245 to $260.

Susquehanna Upgrades Union Pacific to Positive, Raises Price Target to $260

Happy City Holdings Shares Halted On Circuit Breaker To The Downside At $6.08/Share

IPOs

Happy City Holdings Shares Open For Trade at $6.75/Share

As part of its efforts to turbocharge retail trading strategies, Defiance ETFs has launched three new <a href="https://www.benzinga.com/etfs">single-stock ETFs</a> offering daily leveraged and inverse exposure to some of the most talked-about tech stocks: IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>), Oklo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>), and SoundHound AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>). 
These funds come days after Defiance launched the Daily Target 2x Short PLTR ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTZ#NASDAQ">PLTZ</a>), the first leveraged inverse fund to focus on Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>). This fund provides short sellers with a new means to double down, literally, on short-term dips in the contentious software company. The new set includes: Defiance Daily Target 2X Short IONQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONZ#NASDAQ">IONZ</a>) – a fund aiming for a negative 200% of the day&#8217;s action in quantum computing firm IonQ Inc., designed for traders with short-term bearish views on the stock.
Defiance Daily Target 2X Long OKLO ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKLL#NASDAQ">OKLL</a>) – offering 200% daily exposure to Oklo, a nuclear fission and fuel recycling specialist; Defiance Daily Target 2X Long SOUN ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUX#NASDAQ">SOUX</a>) seeks 200% of the daily moves in SoundHound AI, a firm known for its voice AI tech used in cars and connected devices. In contrast to conventional margin-based trading, these ETFs provide investors with leveraged exposure in an ETF wrapper, allowing retail traders to take action on firm beliefs without a margin account or options trading eligibility.
Each fund is constructed for short-term tactical trading, where daily compounding is the game. These are not buy-and-hold vehicles. Holding them longer than one day without active management can create unintended consequences, particularly in volatile markets.
By zeroing in on innovative businesses in emerging fields relevant to these times, from quantum computing and nuclear technology to conversational AI, Defiance is doubling down on the &#8220;high risk, high reward&#8221; set. But with more power comes more volatility. These instruments can zip quickly and violently, so though they might seem like trader candy, they&#8217;re wisely managed with a disciplined approach.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/06/46060843/vanguard-etfs-lead-2025-with-150-billion-inflows-challenging-wall-streets-old-guard">Vanguard ETFs Lead 2025 With $150 Billion Inflows, Challenging Wall Street&#8217;s Old Guard</a></li>
</ul>
Photo: Shutterstock

New ETFs

ETFs

IONQ

IONZ

OKLL

OKLO

PLTR

PLTZ

SOUN

SOUX

New Defiance ETFs Offer 2X Bull And Bear Exposure To IonQ, Oklo And SoundHound AI

<a href="https://www.youtube.com/watch?v=iQAnZXa1Kpg">https://www.youtube.com/watch?v=iQAnZXa1Kpg</a>
&nbsp;

Fed Chair Powell Says Banks Are Free To Provide Banking Services To Crypto Industry, Conduct Activities As Long As Protect Safety And Soundness

Rumors

Happy City Holdings IPO Indicating $6.10/Share On 94K Shares; IPO Priced At $5/Share On 1.1M Shares

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) has reportedly <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">launched its weight-loss</a> drug Wegovy (semaglutide) in India to compete with Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
In March this year, U.S. pharma giant Eli Lilly launched its popular weight loss drug Mounjaro (tirzepatide) in India. It is expected to have the second-largest population of overweight or <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">obese people by 2050</a>.
A Reuters report on Tuesday said that Wegovy, a weekly injection, will be available in pharmacies by the end of this month. It could take some market share away from Eli Lilly. Meanwhile, sales of Eli Lilly's drug Mounjaro rose 60% between April and May, the report highlighted, citing industry analysts.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46050655/novo-nordisks-weight-loss-injection-cagrisema-data-sparks-investors-concern" rel="noreferrer noopener">Novo Nordisk&#8217;s Weight Loss Injection CagriSema Data Sparks Investor Concern</a>
Novo Nordisk told Reuters that Wegovy is available in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg doses. The first three will be priced at 4,336 rupees ($50.7), and the monthly cost will be 17,345 rupees ($201.4), similar to Eli Lilly&#8217;s Mounjaro.
The Reuters report added that Wegovy&#8217;s 1.7 mg dose will be priced at 24,280 rupees ($281.90) and 2.4 mg at 26,015 rupees.
Mounjaro, a once-weekly injection approved by India's drug regulator, is priced at 4,375 Indian rupees ($50.86) for a 5 mg vial and 3,500 rupees for a 2.5 mg vial, its lowest dose, the company told Reuters. Its highest dose is 15 mg.
On Monday, Novo Nordisk announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for updating the Ozempic (once-weekly semaglutide) label to reflect the positive data from the STRIDE peripheral artery disease (PAD) functional outcomes trial.
Following the <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916358" rel="noreferrer noopener">positive</a> opinion from the CHMP, Novo Nordisk expects the European Commission to implement the label update within approximately two months.
Novo Nordisk has also filed for a label expansion of Ozempic in the U.S., and a decision is expected in the last quarter of 2025.
Based on data from the SOUL trial, Novo Nordisk has also filed with the EMA and FDA for a label expansion for Rybelsus.
This could potentially make Rybelsus the first and only oral GLP-1 RA with proven cardiovascular (CV) benefits. A decision is also expected in the second half of 2025.
On Monday, the New England Journal of Medicine (NEJM) published results from Novo Nordisk&#8217;s phase 3 REDEFINE 1 trial of CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46050655/novo-nordisks-weight-loss-injection-cagrisema-data-sparks-investors-concern" rel="noreferrer noopener">complication and without diabetes</a>.
Price Action: NVO stock is up 1.25% at $70.59 at last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46067629/hims-ceo-slams-novo-nordisk-for-anticompetitive-demands-after-ozempic-maker-abruptly-ends-partnership-we-refuse-to-be-strong-armed" target="_blank" rel="noreferrer noopener">Hims CEO Slams Novo Nordisk For &#8216;Anticompetitive Demands&#8217; After Ozempic Maker Abruptly Ends Partnership: &#8216;We Refuse To Be Strong-Armed&#8217;</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Biotech

Large Cap

Health Care

Novo's India Move Could Reshape The Weight-Loss Drug War With Eli Lilly

Hoth Therapeutics' HT-001 Achieves 100% Response Rate&nbsp;in at least one endpoint&nbsp;in Phase 2a Trial in PK Patients for EGFR Inhibitor-Related Skin Toxicities.
Hoth Therapeutics will host a Key Opinion Leader (KOL) event on, at&nbsp;3:30PM EST&nbsp;to highlight recent clinical progress with HT-001, a novel topical therapeutic developed to address EGFR inhibitor-induced skin toxicities in cancer patients. This event will feature insights from derm-oncology and dermatology specialists&nbsp;Jonathan Hale Zippin M.D.,&nbsp;Ph.D., and&nbsp;Adam Friedman M.D., F.A.A.D., who will present interim results from the ongoing Phase 2 trial and discuss how HT-001 could redefine supportive care standards for oncology patients.&nbsp; Access/join the event through the following link:&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4455869-1&amp;h=3734374131&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4454206-1%26h%3D3911180385%26u%3Dhttps%253A%252F%252Fzoom.us%252Fj%252F91353016981%26a%3Dhttps%253A%252F%252Fzoom.us%252Fj%252F91353016981&amp;a=https%3A%2F%2Fzoom.us%2Fj%2F91353016981">https://zoom.us/j/91353016981</a>.
Phase 2a Trial Highlights (CLEER-001)
<ul>
<li>100% of enrolled patients in open-label cohort achieved at least one primary endpoint of clinical dermatologic improvement</li>
<li>Over 65% reported reductions in pain and pruritus (itching)</li>
<li>0% required dose reduction or discontinuation of their EGFRI therapy.</li>
<li>Topical therapy was well tolerated with no serious adverse events.</li>
</ul>
NEW YORK, June 24, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>), a clinical-stage biopharmaceutical company developing targeted therapies for rare and serious inflammatory conditions, today announced that its investigational candidate HT-001 met the primary efficacy endpoint&nbsp;in at least one metric&nbsp;in 100% of patients in its ongoing Phase 2a clinical study (CLEER-001) evaluating treatment for epidermal growth factor receptor inhibitor (EGFRI)-induced cutaneous toxicities.
EGFR inhibitors, used widely to treat non-small cell lung cancer (NSCLC), pancreatic, breast, colorectal, and head and neck cancers, are associated with dermatologic side effects in up to 90% of patients, often resulting in painful rashes, pruritus, dryness, nail changes, and alopecia. These adverse events frequently force dose reductions or treatment discontinuation, limiting therapeutic efficacy and patient outcomes.

HOTH

Hoth Therapeutics' HT-001 Achieves 100% Response In Phase 2a Trial For EGFR Inhibitor-Related Skin Toxicities

Macro Notification

Fed Chair Powell Says In Housing, There's A Longer-Run Shortage That Fed Cannot Affect; Says Absolute Best Thing We Can Do For Housing Is To Restore Price Stability

SLNO

Watching Soleno Therapeutics; Shares Move Higher, M&A Blog Suggests The Co Has Received Takeover Approaches

Trading Halt: Halt status updated at 10:35:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

Comments

ProShares Smart Materials ETF

空売り

ProShares Smart Materials ETF (ARCA:TINT), 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル